Retatrutide vs Ozempic: How They Compare

Ozempic is the brand name for semaglutide when it is prescribed for type 2 diabetes. Retatrutide is a separate, investigational triple-agonist molecule from Eli Lilly that is not yet approved. Both are once-weekly injections, so they frequently get mentioned together. Here's a clear comparison of what is publicly known.

Important: Retatrutide is not FDA-approved and cannot be prescribed. Ozempic is approved. The following is educational information, not medical advice.

Is Ozempic the same as retatrutide?

No. Ozempic is semaglutide, a single-receptor GLP-1 agonist approved to improve blood sugar in type 2 diabetes. Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon, still in clinical trials. They come from different companies (Novo Nordisk markets Ozempic; Eli Lilly is developing retatrutide) and are not interchangeable.

Side-by-side comparison

Retatrutide: the investigational triple agonist

Retatrutide activates three receptors with one molecule. In its Phase 2 obesity trial, the 12 mg weekly dose produced about 24.2% mean weight loss at 48 weeks. It is dosed once weekly, has a roughly 6-day half-life, and is progressing through the Phase 3 TRIUMPH program, with topline results reported through 2026. It remains investigational: not approved and not available by prescription.

Ozempic: approved semaglutide for diabetes

Ozempic is semaglutide approved for improving blood sugar control in adults with type 2 diabetes, alongside diet and exercise, and it also carries an indication to reduce cardiovascular risk in certain patients. (The same molecule is sold as Wegovy for weight management.) Ozempic is a once-weekly injection, started at 0.25 mg and increased gradually under a provider's supervision, with established FDA labeling.

Which is more effective?

Retatrutide's early weight-loss numbers are larger than those typically associated with Ozempic, but Ozempic is primarily a diabetes medicine, and the two have never been compared head-to-head. Retatrutide has also not completed Phase 3. Comparing an investigational drug's Phase 2 figures with an approved drug's established results is not a fair basis for a treatment decision. Only your healthcare provider can advise on approved therapy.

Can I get retatrutide instead of Ozempic?

No. Retatrutide is not approved and cannot be prescribed as an approved medicine. Ozempic and other approved GLP-1 medicines can be, through a provider. Any "retatrutide" sold outside a clinical trial is not FDA-approved and may carry safety and quality risks. Speak with your provider about approved options.

Medical Disclaimer

This page is general educational information, not medical advice. Retatrutide is investigational and not FDA-approved. Trial figures are reported as published in the referenced studies and are not dosing recommendations. RetaPal is a private tracking and reminder app only. It does not recommend, calculate, or suggest doses. Always follow the dose and schedule given by your own prescriber, and consult your healthcare provider before starting, stopping, or changing any medication.

When your provider has set your plan, RetaPal can log each weekly dose and count down to your next injection, private, offline, and never suggesting a dose.